![]() | |
Clinical data | |
---|---|
Trade names | Topiloric, Uriadec |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C13H8N6 |
Molar mass | 248.249 g·mol−1 |
3D model ( JSmol) | |
| |
|
Topiroxostat ( INN; trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia. [1] It was approved for use in Japan in June 2013. [1]
Topiroxostat is a xanthine oxidase inhibitor which reduces serum urate levels. [2]
{{
cite journal}}
: Cite journal requires |journal=
(
help)
![]() | |
Clinical data | |
---|---|
Trade names | Topiloric, Uriadec |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C13H8N6 |
Molar mass | 248.249 g·mol−1 |
3D model ( JSmol) | |
| |
|
Topiroxostat ( INN; trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia. [1] It was approved for use in Japan in June 2013. [1]
Topiroxostat is a xanthine oxidase inhibitor which reduces serum urate levels. [2]
{{
cite journal}}
: Cite journal requires |journal=
(
help)